Is It Better To Be First Or Best? Daiichi Sankyo Shifts R&D Priorities
This article was originally published in The Pink Sheet Daily
Executive Summary
Because regulators and the market have become less accepting of follow-on compounds, the Japanese pharma plans to invest in first-in-class science, pursuing best-in-class opportunities only when it sees a substantial unmet medical need.